PDUFA date nears for GSK plc’s Blenrep (belantamab mafodotin), the U.S. FDA’s Oncologic Drugs Advisory Committee will decide July 17 on whether available data justify the return to market of the ...

Explore Matthews International Corporation's restructuring efforts, asset sales, and challenges in reducing debt. Click for ...

Recent developments illustrate dynamic shifts in the healthcare sector. Trump's spending bill is anticipated to challenge ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

India needs to build a much stronger drug discovery ecosystem to compete globally, says former GSK Pharma MD Annaswamy ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

LEAP addresses those needs head-on with a local-first approach that allows small models to run directly on-device, no cloud ...

The UK's FTSE 100 index fell after reaching record highs, impacted by rising U.S. inflation and potential Bank of England ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep back to markets around the globe. | As GSK's Blenrep makes its return to ...

GSK (GSK) stock in focus as the FDA staff raise safety concerns over Blenrep combo for multiple myeloma ahead of an AdCom ...